Deep Learning Approach for Discovery of In Silico Drugs for Combating COVID-19

Citations Over TimeTop 10% of 2021 papers

Abstract

Early diagnosis of pandemic diseases such as COVID-19 can prove beneficial in dealing with difficult situations and helping radiologists and other experts manage staffing more effectively. The application of deep learning techniques for genetics, microscopy, and drug discovery has created a global impact. It can enhance and speed up the process of medical research and development of vaccines, which is required for pandemics such as COVID-19. However, current drugs such as remdesivir and clinical trials of other chemical compounds have not shown many impressive results. Therefore, it can take more time to provide effective treatment or drugs. In this paper, a deep learning approach based on logistic regression, SVM, Random Forest, and QSAR modeling is suggested. QSAR modeling is done to find the drug targets with protein interaction along with the calculation of binding affinities. Then deep learning models were used for training the molecular descriptor dataset for the robust discovery of drugs and feature extraction for combating COVID-19. Results have shown more significant binding affinities (greater than -18) for many molecules that can be used to block the multiplication of SARS-CoV-2, responsible for COVID-19.

Related Papers

• → How not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR)(2009)465 cited
• → Quantitative Structure-Activity Relationship (QSAR) Paradigm - Hansch Era to New Millennium(2001)55 cited
• → Development of QSAR Model Based on the Key Molecular Descriptors Selection and Computational Toxicology for Prediction of Toxicity of PCBs(2016)4 cited
• Multi-dimensional QSAR Studies on Aurora-A kinase Inhibitors(2020)
• Study the QSAR/QSPR on Compound Molecules(2004)